Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy F Joos

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Current Opinion in Pharmacology|June 18, 2003
Bronchial hyperresponsiveness: too complex to be useful?Guy F Joos
Expert Opinion on Investigational Drugs|January 6, 2010
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary diseaseGuy F Joos
American Journal of Respiratory and Critical Care Medicine|August 7, 2007
Are beta2-agonists safe in patients with acute exacerbations of COPD?Guy F Joos
Polskie Archiwum Medycyny Wewnetrznej|February 11, 2009
Which patients with asthma could benefit from using anti-leukotriene drugs: an evidence based reviewGuy F Joos
Respirology (Carlton, Vic.)|November 21, 2014
Is there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Guy F Joos, Esteban C Gabazza
European Journal of Pharmacology|February 9, 2006
Extending the understanding of sensory neuropeptidesKatelijne O De Swert, Guy F Joos
Current Allergy and Asthma Reports|January 19, 2011
Gene therapy for allergic airway diseasesTania Maes, Kurt G Tournoy, Guy F Joos
International Journal of Chronic Obstructive Pulmonary Disease|December 24, 2016
Efficacy of tiotropium-olodaterol fixed-dose combination in COPDEric Derom, Guy G Brusselle, Guy F Joos
Therapeutic Advances in Respiratory Disease|April 20, 2019
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospectsEric Derom, Guy G Brusselle, Guy F Joos
American Journal of Respiratory Cell and Molecular Biology|April 28, 2012
Targeting interleukin-4 in asthma: lost in translation?Tania Maes, Guy F Joos, Guy G Brusselle
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Current Opinion in Pharmacology|June 18, 2003
Bronchial hyperresponsiveness: too complex to be useful?Guy F Joos
Expert Opinion on Investigational Drugs|January 6, 2010
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary diseaseGuy F Joos
American Journal of Respiratory and Critical Care Medicine|August 7, 2007
Are beta2-agonists safe in patients with acute exacerbations of COPD?Guy F Joos
Polskie Archiwum Medycyny Wewnetrznej|February 11, 2009
Which patients with asthma could benefit from using anti-leukotriene drugs: an evidence based reviewGuy F Joos
Respirology (Carlton, Vic.)|November 21, 2014
Is there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Guy F Joos, Esteban C Gabazza
European Journal of Pharmacology|February 9, 2006
Extending the understanding of sensory neuropeptidesKatelijne O De Swert, Guy F Joos
Current Allergy and Asthma Reports|January 19, 2011
Gene therapy for allergic airway diseasesTania Maes, Kurt G Tournoy, Guy F Joos
International Journal of Chronic Obstructive Pulmonary Disease|December 24, 2016
Efficacy of tiotropium-olodaterol fixed-dose combination in COPDEric Derom, Guy G Brusselle, Guy F Joos
Therapeutic Advances in Respiratory Disease|April 20, 2019
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospectsEric Derom, Guy G Brusselle, Guy F Joos
American Journal of Respiratory Cell and Molecular Biology|April 28, 2012
Targeting interleukin-4 in asthma: lost in translation?Tania Maes, Guy F Joos, Guy G Brusselle
Pageof 10